ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED OPEN-LABEL ACTIVE-CONTROLLED MULTICENTER TRIAL (EMERALD)

Brief description of study

This purpose of this research study is to compare the safety and effectiveness of investigational drug elacestrant to standard hormonal medications that are already approved and used to treat your type of breast cancer. You are being asked to take part in this research study because you have estrogen receptor (ER) positive advanced breast cancer.


Clinical Study Identifier: s18-01304
ClinicalTrials.gov Identifier: NCT03778931
Principal Investigator: Yelena Novik
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.